Hamid Ahmod
Impact in
- Infectious Diseases top 10%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
-
- COVID-19 and healthcare impacts
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Papers in
-
- SARS-CoV-2 and COVID-19 Research 7
- COVID-19 Clinical Research Studies 6
- Oncology 5
- COVID-19 and healthcare impacts 4
- Cancer Immunotherapy and Biomarkers 1
- Journals
- Cancer Cell (3 papers)Nature Cancer (2 papers)Cell Reports Medicine (1 paper)UCL Discovery (University College London) (1 paper)
- Partner nations
- United Kingdom
In The Last Decade
Hamid Ahmod
7 papers receiving 360 citations
Peers
Comparison fields: 5 of 30
- Infectious Diseases 264
- Oncology 153
- Immunology 59
- Health 22
- Modeling and Simulation 10
Countries citing papers authored by Hamid Ahmod
This map shows the geographic impact of Hamid Ahmod's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hamid Ahmod with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hamid Ahmod more than expected).
Fields of papers citing papers by Hamid Ahmod
This network shows the impact of papers produced by Hamid Ahmod. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hamid Ahmod. The network helps show where Hamid Ahmod may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 140 | |
| 2 | 2021 | 69 | |
| 3 | Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer | 2022 | 60 |
| 4 | 2021 | 52 | |
| 5 | 2022 | 19 | |
| 6 | 2022 | 17 | |
| 7 | 2023 | 6 |
About Hamid Ahmod
Hamid Ahmod is a scholar working on Infectious Diseases, Oncology, Immunology, Neurology and Insect Science, having authored 7 papers that have together received 363 indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (7 papers), COVID-19 Clinical Research Studies (6 papers), COVID-19 and healthcare impacts (4 papers), Immunotherapy and Immune Responses (2 papers), Long-Term Effects of COVID-19 (1 paper) and Cancer Immunotherapy and Biomarkers (1 paper). The work is most often cited by research in Infectious Diseases (264 citations), Oncology (153 citations), Immunology (59 citations), Health (22 citations) and Modeling and Simulation (10 citations). Hamid Ahmod has collaborated with scholars based in United Kingdom. Their work appears in journals such as Cancer Cell, Nature Cancer, Cell Reports Medicine and UCL Discovery (University College London).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.